1 min read
Add as a preferred source on Google

Savara Shares Fall 18% After Company Says FDA Will Miss Molgramostim Action Date

The FDA’s review is ongoing, and the agency has not provided a new action date.

A sealed vial and nebulizer mouthpiece sit in a clinical room / TokenPost.ai
A sealed vial and nebulizer mouthpiece sit in a clinical room / TokenPost.ai

Savara Inc. shares fell about 18% in Friday morning trading after the company said the FDA will not meet the Nov. 22 action date for its molgramostim application.

The FDA’s review is ongoing, and no new action date has been provided. The application is for molgramostim inhalation solution, a treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease.

Molgramostim inhalation solution is a recombinant human granulocyte-macrophage colony-stimulating factor.

Riza Dagoc

Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…